The full menu of approved options
From injectable GLP-1 and dual agonists to oral combinations and a lipase inhibitor, the FDA-approved arsenal now spans a wide efficacy range — roughly 2.4% to 20.9% placebo-adjusted weight loss. The right choice depends on your biology, your tolerance, and your goals. This table lays out the entire landscape. Most people who read this are comparing medically supervised weight loss ft options around Fort Myers, FL, so what follows sticks to the details that change in practice.
| Generic Name | Trade Name(s) | Receptor Targets & Class | FDA Status | Placebo-Adjusted Weight Loss Efficacy | Primary Biological Action | Source |
|---|---|---|---|---|---|---|
| Tirzepatide | Zepbound (weight loss), Mounjaro (diabetes) | Dual GLP-1 and GIP receptor agonist | Chronic weight management (FDA-approved 2023) | 17.8%–20.9% (at 15 mg dose) | Slowing gastric emptying, increasing satiety, and improving glycemic control via dual-action central signaling | 2, Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Semaglutide | Wegovy (weight loss), Ozempic (diabetes) | Selective GLP-1 receptor agonist | Chronic weight management (FDA-approved 2021) | 12.0%–12.4% | Slowing gastric emptying and central appetite suppression via the hypothalamus to reduce cravings | 3, 2, Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Phentermine/topiramate | Qsymia | Substituted amphetamine (Sympathomimetic amine) / GABA modulator & carbonic anhydrase inhibitor | Chronic weight management (also indicated for short-term) | 8.8%–10.2% | Appetite suppression via norepinephrine release and increased satiety via neurotransmitter modification | Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Liraglutide | Saxenda (weight loss), Victoza (diabetes) | Selective GLP-1 receptor agonist | Chronic weight management | 4.0%–5.4% | Regulation of appetite and calorie intake by slowing gastric emptying and increasing feelings of fullness | Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Naltrexone/bupropion | Contrave | Opioid antagonist / Norepinephrine-dopamine reuptake inhibitor (NDRI) | Chronic weight management | 4.0%–5.0% | Targets the reward system (mesolimbic) and hypothalamus to reduce food cravings and appetite | Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Phentermine | Adipex-P, Lomaira | Substituted amphetamine (Sympathomimetic amine; TAAR1 agonist) | Short-term use (up to 12 weeks) | 3.0%–4.0% (or ~5 kg / 11 lb) | Stimulation of norepinephrine release to suppress appetite | Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Orlistat | Xenical (Prescription), Alli (OTC) | Gastric and pancreatic lipase inhibitor (Non-receptor) | Chronic weight management | 2.4%–4.0% (or ~3 kg / 6.6 lb) | Inhibition of gastrointestinal lipases to prevent the absorption of dietary fat in the intestines | 3, Background Knowledge, Inferred, Wikipedia Anti-Obesity Medications |
| Sibutramine | Meridia | Not in source | Withdrawn | Not in source | Appetite suppression |
Reading the table
Efficacy climbs with receptor coverage: selective GLP-1 (Wegovy) hits ~12%, the dual GLP-1/GIP agonist tirzepatide (Zepbound) reaches ~18–21% at the top dose, and oral/combination options (Qsymia, Contrave) occupy the 4–10% band with a different side-effect profile. Lower efficacy is not worse — it is often the right trade for someone who tolerates oral meds or needs short-term support.
The short version
- The article surveys seven FDA-approved weight-loss medications whose placebo-adjusted efficacy spans roughly 2.4% to 20.9% of body weight.
- Tirzepatide (Zepbound), a dual GLP-1 and GIP agonist approved in 2023, leads with 17.8%-20.9% weight loss at the 15 mg dose.
- Semaglutide (Wegovy), a selective GLP-1 receptor agonist approved in 2021, produces 12.0%-12.4%, while liraglutide (Saxenda) reaches only 4.0%-5.4%.
- Qsymia (phentermine/topiramate) yields 8.8%-10.2% and Contrave (naltrexone/bupropion) 4.0%-5.0%, with the latter specifically targeting the brain's mesolimbic reward system.
- Phentermine alone is approved only for short-term use up to 12 weeks and yields 3.0%-4.0%, roughly 5 kg or 11 lb.
- Orlistat (Xenical/Alli) is a non-receptor lipase inhibitor producing 2.4%-4.0% by blocking dietary fat absorption, and sibutramine (Meridia) is withdrawn.
Choose with a provider, not a comment section
Every option in this table is a prescription for a reason. Get matched with a local weight-loss provider who can match your profile to the right class — free, no obligation.
